Jon K Bjerregaard

Summary

Affiliation: Odense University Hospital
Country: Denmark

Publications

  1. doi Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients
    J K Bjerregaard
    Department of Oncology, Odense University Hospital, Denmark
    Eur J Cancer 49:98-105. 2013
  2. doi Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy
    Jon K Bjerregaard
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Int J Radiat Oncol Biol Phys 83:909-15. 2012
  3. ncbi Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer
    Jon K Bjerregaard
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, Odense C, Denmark
    Radiother Oncol 92:226-30. 2009
  4. doi Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum
    Katrine R Schoennemann
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, 5000, Odense C, Denmark
    Gastric Cancer 14:219-25. 2011
  5. doi Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer
    Katrine R Schønnemann
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 53:385-91. 2014
  6. doi Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
    Finn Ole Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Acta Oncol 50:574-7. 2011

Collaborators

Detail Information

Publications6

  1. doi Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients
    J K Bjerregaard
    Department of Oncology, Odense University Hospital, Denmark
    Eur J Cancer 49:98-105. 2013
    ..Therefore, we investigated patient baseline characteristics, therapy choices and survival in a complete cohort of patients with PC...
  2. doi Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy
    Jon K Bjerregaard
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Int J Radiat Oncol Biol Phys 83:909-15. 2012
    ..We describe the results in 178 patients treated from 2001 to 2010 and have developed a prognostic model for both survival and the possibility of a subsequent resection in these patients...
  3. ncbi Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer
    Jon K Bjerregaard
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, Odense C, Denmark
    Radiother Oncol 92:226-30. 2009
    ..Treatment options range from palliative chemotherapy to chemoradiotherapy (CRT). Several studies have shown that a number of patients become resectable after complementary treatment prior to surgery...
  4. doi Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum
    Katrine R Schoennemann
    Department of Oncology, Odense University Hospital, Sdr Boulevard 29, 5000, Odense C, Denmark
    Gastric Cancer 14:219-25. 2011
    ..Inspired by therapy in metastatic colorectal cancer, a combination of cetuximab and irinotecan (Cetiri) was chosen for second-line therapy in GEC patients. We report our experience with Cetiri as second-line therapy in patients with GEC...
  5. doi Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer
    Katrine R Schønnemann
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 53:385-91. 2014
    ..The purpose was to examine characteristics, treatment and outcome in an unselected, prospectively registered complete population of patients with gastro-oesophageal adenocarcinoma cancer (GEA)...
  6. doi Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer
    Finn Ole Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Acta Oncol 50:574-7. 2011
    ..The efficacy and safety of concurrent administration of irinotecan with the two monoclonal antibodies cetuximab and bevacizumab as fourth line therapy in heavily pretreated patients with metastatic colorectal cancer were evaluated...